Trimel Pharmaceuticals - A closer look at Tefina Phase II FOD results

While Trimel (TSX:TRL) continues to work on securing a commercial licensing transaction for its recently approved Natesto testosterone nasal gel, the firm recently provided further encouraging data on its 253-patient Phase II study for Tefina in female orgasmic disorder (FOD). Trimel continues to analyse the data and plans to meet with the FDA in H214, ahead of the next clinical study.

Trimel is a Canadian specialty pharmaceutical company. Its lead products, Natesto and Tefina, deliver testosterone through a bio-adhesive nasal gel drug delivery technology platform, for male hypogonadism and female orgasmic disorder (FOD), respectively.

To view the full research report, click here: http://www.edisoninvestmentresearch.com/research/report/trimel-pharmaceuticals4

Click here to view all of Edison's recently published research.

Trilogy International Pa... (TSX:TRL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024